Author: admin

The Mild Dry Eye market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mild Dry Eye pipeline products will significantly revolutionize the Mild Dry Eye market dynamics.

DelveInsight’s “Mild Dry Eye Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Mild Dry Eye, historical and forecasted epidemiology as well as the Mild Dry Eye market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mild Dry Eye market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Mild Dry Eye market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mild Dry Eye Market Forecast

Some of the key facts of the Mild Dry Eye Market Report:

• The Mild Dry Eye market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that it will hold a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to present the topline results from its Phase 3 clinical trials of reproxalap for dry eye disease. U.S. participants can dial (833) 470-1428, while international callers can use (404) 975-4839, using access code 127477. A live audio webcast will be available in the “Investors & Media” section of Aldeyra’s website at ir.aldeyra.com. The recording will remain accessible on the site for 90 days following the event.

• In April 2025, The U.S. Food and Drug Administration (FDA) declined to approve Aldeyra Therapeutics’ Dry Eye treatment, reproxalap, citing insufficient efficacy data. This marks the second rejection, following a similar outcome in 2023. The FDA recommends at least one additional trial to demonstrate the drug’s effectiveness.

• In February 2025, Cambium Bio revealed that the FDA has approved the protocol for its Phase III clinical trials of Elate Ocular, aimed at treating moderate to severe Dry Eye.

• In January 2025, Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company focused on developing innovative treatments for ophthalmic conditions, has announced the completion of the final patient visit in its Phase III clinical trial of ST-100 (vezocolmitide), its lead therapeutic candidate for Dry Eye.

• In December 2024, The FDA issued a nationwide recall of a specific single-use eye drop product. Alcon Laboratories voluntarily recalled one lot (Lot 10101) of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after a customer reported possible fungal contamination in a vial. This recall is limited to the identified lot only.

• In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on discovering and developing innovative therapies for immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled clinical trial of 0.25% reproxalap ophthalmic solution. This investigational drug candidate aims to treat Dry Eye. Reproxalap showed statistical superiority to the vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), a symptom of Mild Dry Eye accepted by the U.S. Food and Drug Administration (FDA).

• In January 2024, Alcon, headquartered in Switzerland, announced the success of its Dry Eye medication AR-15512 in meeting primary endpoints in two Phase III trials, namely COMET-2 and COMET-3. With encouraging results from these trials, the company intends to submit a new drug application (NDA) for AR-15512 to the US Food and Drug Administration (FDA) by mid-2024, as outlined in a press release dated January 9th.

• In January 2024, Stuart Therapeutics, a biopharmaceutical firm based in the United States, has initiated a Phase III clinical study for their drug candidate vezocolmitide (ST-100) targeting patients with Mild Dry Eye. This randomized, placebo-controlled trial seeks to assess the effectiveness and safety of a single dose of the ophthalmic solution compared to a placebo. The trial is set to enroll 320 participants

• The anticipated launch of new therapies, including RGN-259, Tavilermide (MIM-D3), and AR-15512, is expected to drive changes in the total market size of DED in the coming years.

• According to DelveInsight’s assessment, the estimated total number of diagnosed prevalent cases of DED in the 7MM was approximately 54.7 million in 2023.

• In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of DED among European countries, with around 6.1 million cases, followed by Germany with approximately 5 million. Spain, meanwhile, had the lowest prevalence, with 2.1 million cases

• Key Mild Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

• Key Mild Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

• The Mild Dry Eye epidemiology based on gender analyzed that females are more affected by Mild Dry Eye than males

Mild Dry Eye Overview

Mild dry eye is a common condition where the eyes do not produce enough tears or the tears evaporate too quickly, leading to insufficient lubrication. Symptoms may include slight eye discomfort, redness, a gritty or burning sensation, and occasional blurred vision. It is typically triggered by environmental factors, screen time, aging, or contact lens use. Though mild, if left unmanaged, it can worsen over time. Treatment often involves using over-the-counter artificial tears, taking screen breaks, staying hydrated, and managing environmental triggers.

Get a Free sample for the Mild Dry Eye Market Report –

https://www.delveinsight.com/report-store/mild-dry-eye-market

Mild Dry Eye Market

The dynamics of the Mild Dry Eye market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“Of the emerging therapies, MC2-03 (mc2 therapeutics), PL9643 (Palatin Technologies),and many other compelling treatments are expected to change the market scenario of Mild Dry Eye in the upcoming years.”

Mild Dry Eye Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mild Dry Eye Epidemiology Segmentation:

The Mild Dry Eye market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Mild Dry Eye

• Prevalent Cases of Mild Dry Eye by severity

• Gender-specific Prevalence of Mild Dry Eye

• Diagnosed Cases of Episodic and Chronic Mild Dry Eye

Download the report to understand which factors are driving Mild Dry Eye epidemiology trends @ Mild Dry Eye Epidemiological Insights

Mild Dry Eye Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mild Dry Eye market or expected to get launched during the study period. The analysis covers Mild Dry Eye market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mild Dry Eye Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mild Dry Eye Therapies and Key Companies

• PL9643: Palatin Technologies

• NOV03: Novaliq

• CyclASol: Novaliq

• MC2-03: mc2 therapeutics

To know more about Mild Dry Eye treatment, visit @ Mild Dry Eye Medications

Scope of the Mild Dry Eye Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Mild Dry Eye Companies: Palatin Technologies, Novaliq, mc2 therapeutics, and others

• Key Mild Dry Eye Therapies: PL9643, NOV03, CyclASol, MC2-03, and others

• Mild Dry Eye Therapeutic Assessment: Mild Dry Eye current marketed and Mild Dry Eye emerging therapies

• Mild Dry Eye Market Dynamics: Mild Dry Eye market drivers and Mild Dry Eye market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Mild Dry Eye Unmet Needs, KOL’s views, Analyst’s views, Mild Dry Eye Market Access and Reimbursement

Discover more about therapies set to grab major Mild Dry Eye market share @ Mild Dry Eye Treatment Landscape

Table of Contents

1. Mild Dry Eye Market Report Introduction

2. Executive Summary for Mild Dry Eye

3. SWOT analysis of Mild Dry Eye

4. Mild Dry Eye Patient Share (%) Overview at a Glance

5. Mild Dry Eye Market Overview at a Glance

6. Mild Dry Eye Disease Background and Overview

7. Mild Dry Eye Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild Dry Eye

9. Mild Dry Eye Current Treatment and Medical Practices

10. Mild Dry Eye Unmet Needs

11. Mild Dry Eye Emerging Therapies

12. Mild Dry Eye Market Outlook

13. Country-Wise Mild Dry Eye Market Analysis (2019–2032)

14. Mild Dry Eye Market Access and Reimbursement of Therapies

15. Mild Dry Eye Market Drivers

16. Mild Dry Eye Market Barriers

17. Mild Dry Eye Appendix

18. Mild Dry Eye Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mild Dry Eye Market Growth Projections 2023-2032: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics

DelveInsight’s “Retinal Detachment Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Retinal Detachment Disorder, historical and forecasted epidemiology as well as the Retinal Detachment Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Retinal Detachment Disorder, offering comprehensive insights into the Retinal Detachment Disorder revenue trends, prevalence, and treatment landscape. The report delves into key Retinal Detachment Disorder statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Retinal Detachment Disorder therapies. Additionally, we cover the landscape of Retinal Detachment Disorder clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Retinal Detachment Disorder treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Retinal Detachment Disorder space.

To Know in detail about the Retinal Detachment Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Retinal Detachment Disorder Market Forecast

Some of the key facts of the Retinal Detachment Disorder Market Report:

• The Retinal Detachment Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, Pykus Therapeutics, Inc. (“Pykus” or the “Company”) has announced encouraging clinical results from its ongoing pilot study of PYK-2101, its lead product candidate—a focal hydrogel retinal sealant—used in retinal detachment surgery. The trial showed a retinal reattachment rate surpassing the FDA’s benchmark for ocular endotamponades, highlighted the potential for faster vision restoration, and reported no safety issues.

• In December 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is advancing DURAVYU™ (formerly EYP-1901) as a potentially game-changing therapy for VEGF-mediated retinal diseases. This treatment utilizes EyePoint’s proprietary Durasert E™ sustained-release technology to deliver vorolanib, a powerful, selective, and patent-protected tyrosine kinase inhibitor (TKI), through a solid bioerodible insert. Vorolanib offers a novel therapeutic strategy by acting as a pan-VEGF receptor inhibitor, targeting all VEGF receptors. Additionally, in an in-vivo model of retinal detachment, vorolanib showed neuroprotective properties and potential antifibrotic effects by also inhibiting PDGF.

• Key Retinal Detachment Disorder Companies: ONL Therapeutics, Allergan, Bausch & Lomb Incorporated, Pacific Eye Associates, Allegro Ophthalmics, LLC, ThromboGenics, Aldeyra Therapeutics, Inc., and others

• Key Retinal Detachment Disorder Therapies: ONL1204 Ophthalmic Solution, Brimonidine Implant, Vitrase, ranibizumab, Luminate®, ocriplasmin, ADX-2191, and others

• The Retinal Detachment Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Retinal Detachment Disorder pipeline products will significantly revolutionize the Retinal Detachment Disorder market dynamics.

• Retinal detachment affects approximately 10 to 18 people per 100,000 population annually worldwide

• Most commonly occurs in individuals aged 50 years and older, especially those with age-related changes in the vitreous

• The prevalence of Retinal detachment in Males is more frequently affected than females

• High myopia (nearsightedness) is a major risk factor and increases the risk of retinal detachment by 7 to 10 times

• Individuals who have undergone cataract surgery face a higher risk, especially within the first few years post-operation

Retinal Detachment Disorder Overview

Retinal Detachment is a serious eye disorder where the retina, a thin layer of tissue at the back of the eye, separates from its underlying supportive tissue. This detachment disrupts the retina’s function, potentially leading to vision loss or blindness if not treated promptly. It often results from aging, injury, or underlying eye conditions and may cause symptoms like sudden flashes of light, floaters, or a shadow over the visual field. Immediate medical attention is crucial to prevent permanent vision damage.

Get a Free sample for the Retinal Detachment Disorder Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/retinal-detachment-disorder-market

Retinal Detachment Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Retinal Detachment Disorder Epidemiology Segmentation:

The Retinal Detachment Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Retinal Detachment Disorder

• Prevalent Cases of Retinal Detachment Disorder by severity

• Gender-specific Prevalence of Retinal Detachment Disorder

• Diagnosed Cases of Episodic and Chronic Retinal Detachment Disorder

Download the report to understand which factors are driving Retinal Detachment Disorder epidemiology trends @ Retinal Detachment Disorder Epidemiology Forecast

Retinal Detachment Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Retinal Detachment Disorder market or expected to get launched during the study period. The analysis covers Retinal Detachment Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Retinal Detachment Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Retinal Detachment Disorder Therapies and Key Companies

• ONL1204 Ophthalmic Solution: ONL Therapeutics

• Brimonidine Implant: Allergan

• Vitrase: Bausch & Lomb Incorporated

• ranibizumab: Pacific Eye Associates

• Luminate®: Allegro Ophthalmics, LLC

• ocriplasmin: ThromboGenics

• ADX-2191: Aldeyra Therapeutics, Inc.

Discover more about therapies set to grab major Retinal Detachment Disorder market share @ Retinal Detachment Disorder Treatment Landscape

Retinal Detachment Disorder Market Drivers

• Increasing prevalence of retinal disorders due to aging populations and rising incidence of diabetes and myopia

• Advancements in surgical techniques such as scleral buckling, vitrectomy, and pneumatic retinopexy improving success rates

• Rising awareness and early diagnosis through routine eye exams and better imaging technologies like OCT and fundus photography

• Growing healthcare infrastructure in developing regions leading to improved access to retinal care and treatments

Retinal Detachment Disorder Market Barriers

• High cost of surgical treatments and retinal devices, limiting affordability in low- and middle-income countries

• Limited number of skilled ophthalmic surgeons, especially in rural and underdeveloped areas

• Delayed diagnosis due to asymptomatic onset in early stages and lack of awareness among patients

• Post-surgical complications and recurrence rates affecting treatment outcomes and patient confidence

Scope of the Retinal Detachment Disorder Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Retinal Detachment Disorder Companies: ONL Therapeutics, Allergan, Bausch & Lomb Incorporated, Pacific Eye Associates, Allegro Ophthalmics, LLC, ThromboGenics, Aldeyra Therapeutics, Inc., and others

• Key Retinal Detachment Disorder Therapies: ONL1204 Ophthalmic Solution, Brimonidine Implant, Vitrase, ranibizumab, Luminate®, ocriplasmin, ADX-2191, and others

• Retinal Detachment Disorder Therapeutic Assessment: Retinal Detachment Disorder current marketed and Retinal Detachment Disorder emerging therapies

• Retinal Detachment Disorder Market Dynamics: Retinal Detachment Disorder market drivers and Retinal Detachment Disorder market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Retinal Detachment Disorder Unmet Needs, KOL’s views, Analyst’s views, Retinal Detachment Disorder Market Access and Reimbursement

To know more about Retinal Detachment Disorder companies working in the treatment market, visit @ Retinal Detachment Disorder Clinical Trials and Therapeutic Assessment

Table of Contents

1. Retinal Detachment Disorder Market Report Introduction

2. Executive Summary for Retinal Detachment Disorder

3. SWOT analysis of Retinal Detachment Disorder

4. Retinal Detachment Disorder Patient Share (%) Overview at a Glance

5. Retinal Detachment Disorder Market Overview at a Glance

6. Retinal Detachment Disorder Disease Background and Overview

7. Retinal Detachment Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Retinal Detachment Disorder

9. Retinal Detachment Disorder Current Treatment and Medical Practices

10. Retinal Detachment Disorder Unmet Needs

11. Retinal Detachment Disorder Emerging Therapies

12. Retinal Detachment Disorder Market Outlook

13. Country-Wise Retinal Detachment Disorder Market Analysis (2019–2032)

14. Retinal Detachment Disorder Market Access and Reimbursement of Therapies

15. Retinal Detachment Disorder Market Drivers

16. Retinal Detachment Disorder Market Barriers

17. Retinal Detachment Disorder Appendix

18. Retinal Detachment Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinal Detachment Disorder Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | ONL Therapeutics, Allergan, Bausch & Lomb Incorporated, Pacific Eye Associates

DelveInsight’s “Astigmatism Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Astigmatism, historical and forecasted epidemiology as well as the Astigmatism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Astigmatism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Astigmatism Market Forecast

Some of the key facts of the Astigmatism Market Report:

• The Astigmatism market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

• In January 2025, Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global leader in eye health, has announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union, following CE Mark approval received late last year. The enVista Aspire IOLs feature innovative Intermediate Optimized optics, offering an extended depth of focus, combined with the trusted enVista® platform to meet the visual demands of the modern, digital lifestyle. For patients with astigmatism, the enVista Aspire Toric IOLs present a reliable solution during cataract surgery, with a +0.90 cylinder design capable of correcting less than one diopter of corneal astigmatism.

• Key Astigmatism Companies: Technolas Perfect Vision GmbH, Abbott Medical Optics, Bausch & Lomb Incorporated, Durrie Vision, Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, CooperVision, Carl Zeiss Meditec AG, Seed Co., Ltd, Essilor Group, and others

• The Astigmatism market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Astigmatism pipeline products will significantly revolutionize the Astigmatism market dynamics.

Astigmatism Overview

Astigmatism is a common vision condition caused by an irregularly shaped cornea or lens, leading to blurred or distorted vision. Instead of being perfectly round, the cornea or lens is shaped more like a football, which prevents light from focusing properly on the retina. This can cause difficulty seeing clearly at any distance. Astigmatism often occurs alongside nearsightedness or farsightedness and can be corrected with glasses, contact lenses, or refractive surgery.

Get a Free sample for the Astigmatism Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/astigmatism-market

Signs and Symptoms of Astigmatism and Associated Risk Factors

Astigmatism manifests with symptoms that can vary in severity. Common signs include blurred or distorted vision, eyestrain, headaches, and difficulties seeing clearly at night. Individuals with astigmatism may also experience squinting or frequent changes in glasses or contact lens prescriptions. While the exact cause of astigmatism is not always clear, certain risk factors contribute to its development. These include genetics, eye injuries, and conditions such as keratoconus. Understanding these risk factors aids in identifying individuals who may be more susceptible to astigmatism and implementing preventive measures.

Diagnosing Astigmatism: A Comprehensive Eye Examination

Diagnosing astigmatism involves a comprehensive eye examination conducted by an optometrist or ophthalmologist. The examination includes a review of medical history, visual acuity tests, and refraction assessment to determine the extent and type of refractive error. Specialized instruments like keratometers and corneal topographers may be used to measure the curvature of the cornea and identify irregularities contributing to astigmatism. Early and accurate diagnosis is crucial for prescribing corrective lenses or exploring other treatment options.

Astigmatism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Astigmatism Epidemiology Segmentation:

The Astigmatism market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Astigmatism

• Prevalent Cases of Astigmatism by severity

• Gender-specific Prevalence of Astigmatism

• Diagnosed Cases of Episodic and Chronic Astigmatism

Download the report to understand which factors are driving Astigmatism epidemiology trends @ Astigmatism Epidemiology Forecast

Evolving Treatment Outlook for Astigmatism

The treatment of astigmatism primarily focuses on correcting the refractive error to improve visual acuity. The main treatment options include eyeglasses and contact lenses, designed to compensate for the irregular corneal shape and provide clear vision. Refractive surgery, such as LASIK or PRK, is another option for those seeking a more permanent solution. These surgical procedures reshape the cornea to enhance its focusing abilities. While not all individuals with astigmatism are candidates for surgery, technological advancements continue to refine these procedures, expanding treatment options for a broader range of patients.

Market Outlook and Growth Factors in Astigmatism Research

The market for astigmatism correction is influenced by technological advancements in eyewear, contact lenses, and refractive surgery. The increasing prevalence of astigmatism worldwide contributes to the market’s growth. Innovative lens designs, materials, and surgical techniques play a role in meeting the diverse needs of individuals with astigmatism. Moreover, a growing emphasis on vision correction and eye care awareness contributes to the demand for effective and accessible treatments. Collaborations between eyewear manufacturers, healthcare providers, and research institutions drive progress in astigmatism management, enhancing the market’s outlook for improved visual outcomes and enhanced quality of life for affected individuals.

Astigmatism Treatment Devices and Key Companies

• Laser-assisted Astigmatic keratotomy: Technolas Perfect Vision GmbH

• iFS Femtosecond Laser System: Abbott Medical Optics

• Akreos Toric IOL: Bausch & Lomb Incorporated

• Excimer Laser: Durrie Vision

• Toric IOL (SN60T3): Alcon Research

Discover more about therapies set to grab major Astigmatism market share @ Astigmatism Medications

Astigmatism Market Drivers

• Rising prevalence of refractive errors

• Technological advancements

• Growing awareness and screening programs

• Aging population

• Expanding health insurance coverage

Astigmatism Market Barriers

• High cost of advanced treatment options

• Limited awareness in rural areas

• Shortage of ophthalmologists in certain regions

• Side effects and risks associated with surgical correction

• Economic disparities

Scope of the Astigmatism Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Astigmatism Companies: Technolas Perfect Vision GmbH, Abbott Medical Optics, Bausch & Lomb Incorporated, Durrie Vision, Novartis AG, SEA VISION S.r.l, Johnson & Johnson Services, Inc, CooperVision, Carl Zeiss Meditec AG, Seed Co., Ltd, Essilor Group, and others

• Astigmatism Therapeutic Assessment: Astigmatism current marketed and Astigmatism emerging therapies

• Astigmatism Market Dynamics: Astigmatism market drivers and Astigmatism market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Astigmatism Unmet Needs, KOL’s views, Analyst’s views, Astigmatism Market Access and Reimbursement

To know more about Astigmatism companies working in the treatment market, visit @ Astigmatism Clinical Trials and Therapeutic Assessment

Table of Contents

1. Astigmatism Market Report Introduction

2. Executive Summary for Astigmatism

3. SWOT analysis of Astigmatism

4. Astigmatism Patient Share (%) Overview at a Glance

5. Astigmatism Market Overview at a Glance

6. Astigmatism Disease Background and Overview

7. Astigmatism Epidemiology and Patient Population

8. Country-Specific Patient Population of Astigmatism

9. Astigmatism Current Treatment and Medical Practices

10. Astigmatism Unmet Needs

11. Astigmatism Emerging Therapies

12. Astigmatism Market Outlook

13. Country-Wise Astigmatism Market Analysis (2019–2032)

14. Astigmatism Market Access and Reimbursement of Therapies

15. Astigmatism Market Drivers

16. Astigmatism Market Barriers

17. Astigmatism Appendix

18. Astigmatism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Astigmatism Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Technolas Perfect Vision GmbH, Abbott Medical Optics, Bausch & Lomb Inc, Durrie Vision, Novartis AG, SEA VISION

“Myositis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myositis Market.

The Myositis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myositis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myositis treatment therapies with a considerable amount of success over the years.

• Myositis companies working in the treatment market are JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others, are developing therapies for the Myositis treatment

• Emerging Myositis therapies in the different phases of clinical trials are- HuABC2, PF1801, PN-101, M5049, and others are expected to have a significant impact on the Myositis market in the coming years.

• In March 2025, Abcuro, Inc., a clinical-stage biotech firm focused on treating autoimmune diseases and cancer by precisely targeting cytotoxic T cells, announced it will present safety, pharmacokinetic, and pharmacodynamic findings from its Phase 1 clinical trial of ulviprubart (ABC008) for inclusion body myositis (IBM) at the upcoming American Academy of Neurology (AAN) Annual Meeting.

• In February 2025, Abcuro secured $200 million in Series C funding to advance the development of its first-in-class therapy for inclusion body myositis. The funding will support the completion of the registrational Phase 2/3 MUSCLE trial evaluating ulviprubart, as well as the preparation for its Biologics License Application (BLA) submission and eventual commercial launch.

• In November 2024, argenx has chosen to advance the development of efgartigimod SC (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA trial for adults with idiopathic inflammatory myopathies. This decision follows positive topline results from the Phase 2 segment, where the study met its primary endpoint by showing a statistically significant improvement in the mean total improvement score (TIS) at Week 24. Moreover, efgartigimod SC demonstrated favorable outcomes across all six core TIS measures compared to placebo.

Myositis Overview

Myositis is a rare autoimmune disease characterized by inflammation and weakness of the skeletal muscles, particularly those closest to the trunk of the body. It is classified as an idiopathic inflammatory myopathy, meaning that its exact cause is unknown. However, it is believed to involve an abnormal immune response in which the body’s immune system mistakenly attacks its own muscles.

Get a Free Sample PDF Report to know more about Myositis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myositis-pipeline-insight

Emerging Myositis Drugs Under Different Phases of Clinical Development Include:

• HuABC2: JN Biosciences

• PF1801: ImmunoForge

• PN-101: Paean Biotechnology Inc.

• M5049: Merck KGaA

Myositis Route of Administration

Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Inhalation

• Inhalation/Intravenous/Oral

• Intranasal

• Intravenous

• Intravenous/ Subcutaneous

• NA

• Oral

• Oral/intranasal/subcutaneous

• Parenteral

• Subcutaneous

Myositis Molecule Type

Myositis Products have been categorized under various Molecule types, such as

• Antibody

• Antisense oligonucleotides

• Immunotherapy

• Monoclonal antibody

• Peptides

• Protein

• Recombinant protein

• Small molecule

• Stem Cell

• Vaccine

Myositis Pipeline Therapeutics Assessment

• Myositis Assessment by Product Type

• Myositis By Stage and Product Type

• Myositis Assessment by Route of Administration

• Myositis By Stage and Route of Administration

• Myositis Assessment by Molecule Type

• Myositis by Stage and Molecule Type

DelveInsight’s Myositis Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Myositis product details are provided in the report. Download the Myositis pipeline report to learn more about the emerging Myositis therapies

Some of the key companies in the Myositis Therapeutics Market include:

Key companies developing therapies for Myositis are – F. Hoffmann-La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Bausch Health Companies Inc., Accord Healthcare, Genentech, Inc, Johnson & Johnson Services, Inc., Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy’s Laboratories Ltd, Abbott, Bristol-Myers Squibb Company, GSK plc, Merz Pharma, Akorn, Incorporated, and others.

Myositis Pipeline Analysis:

The Myositis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myositis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myositis Treatment.

• Myositis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Myositis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myositis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myositis drugs and therapies

Myositis Pipeline Market Drivers

• Growing cases of chronic muscle inflammation, continuous advancement in technology, increased injuries of muscle are some of the important factors that are fueling the Myositis Market.

Myositis Pipeline Market Barriers

• However, high cost of drugs, lack of approved therapies and other factors are creating obstacles in the Myositis Market growth.

Scope of Myositis Pipeline Drug Insight

• Coverage: Global

• Key Myositis Companies: JN Biosciences, ImmunoForge, Paean Biotechnology Inc., Merck KGaA, and others

• Key Myositis Therapies: HuABC2, PF1801, PN-101, M5049, and others

• Myositis Therapeutic Assessment: Myositis current marketed and Myositis emerging therapies

• Myositis Market Dynamics: Myositis market drivers and Myositis market barriers

Request for Sample PDF Report for Myositis Pipeline Assessment and clinical trials

Table of Contents

1. Myositis Report Introduction

2. Myositis Executive Summary

3. Myositis Overview

4. Myositis- Analytical Perspective In-depth Commercial Assessment

5. Myositis Pipeline Therapeutics

6. Myositis Late Stage Products (Phase II/III)

7. Myositis Mid Stage Products (Phase II)

8. Myositis Early Stage Products (Phase I)

9. Myositis Preclinical Stage Products

10. Myositis Therapeutics Assessment

11. Myositis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myositis Key Companies

14. Myositis Key Products

15. Myositis Unmet Needs

16 . Myositis Market Drivers and Barriers

17. Myositis Future Perspectives and Conclusion

18. Myositis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myositis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, Genentech, Johnson & Johnson

“Myocardial Infarction Treatment Market”

(Albany, USA) DelveInsight’s “Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Myocardial Infarction market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Myocardial Infarction market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Myocardial Infarction treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Myocardial Infarction market.

Request for a Free Sample Report @ Myocardial Infarction Market Forecast

Some facts of the Myocardial Infarction Market Report are:

• The Myocardial Infarction market size in 7MM will increase at a CAGR of 1.61% due to increasing awareness of the disease and launch of the emerging therapy.
• The Myocardial Infarction market size was valued approximately USD 21,750 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In August 2024, CellProthera announced a successful pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA), bringing the company closer to launching a pivotal Phase III trial for its cell therapy targeting myocardial infarction. The France-based company stated that the FDA supported the trial design, which includes a two-year follow-up. The trial will assess the therapy’s effectiveness in preventing future heart diseases.
• In February 2024, Australian CSL announced the topline results from the Phase III AEGIS-II trial of CSL112 in patients after an acute myocardial infarction (MI). The results revealed that the drug did not achieve its primary endpoint of reducing the risk of major adverse cardiovascular events (MACE) within 90 days.
• Estimates suggest that the United States will hold the largest share of the Myocardial Infarction Market, with a value of approximately USD 16,300 million in 2023, driven by a higher number of cases and relatively higher treatment costs.
• In 2023, the total number of diagnosed prevalent cases of Myocardial Infarction across the 7MM was approximately 15.5 million, with expectations of growth during the forecast period.
• In 2023, the United States had approximately 8 million diagnosed prevalent cases of Myocardial Infarction.
• In 2023, the United States represented the largest share of the Myocardial Infarction prevalent population, accounting for approximately 55% of the 7MM. Meanwhile, EU4 and the UK contributed around 35%, and Japan made up about 10% of the total population share.
• DelveInsight estimates indicate that in 2023, the United States had approximately 3.2 million cases of STEMI and 5 million cases of NSTEMI. The prevalence is expected to rise throughout the forecast period.
• Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
• Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal®, Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others
• The Myocardial Infarction epidemiology based on gender analyzed that the prevalence of myocardial infarction (MI) is more common among males as compared to females
• The Myocardial Infarction market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.

Myocardial Infarction Overview

Myocardial infarction, commonly known as a heart attack, occurs when blood flow to a part of the heart muscle is blocked, typically due to a blood clot in a coronary artery. Myocardial infarction causes often include coronary artery disease, high cholesterol, smoking, hypertension, diabetes, and a sedentary lifestyle. Myocardial infarction symptoms can vary but commonly involve chest pain or discomfort, shortness of breath, nausea, sweating, and pain radiating to the arm, jaw, or back.

Myocardial infarction diagnosis is usually confirmed through ECG tests, blood markers like troponin, and imaging techniques. Prompt myocardial infarction treatment is critical and may involve medications such as antiplatelets, thrombolytics, and beta-blockers, as well as procedures like angioplasty or coronary artery bypass surgery. Myocardial infarction recovery depends on the extent of heart damage and timely medical intervention.

Myocardial infarction prevention strategies focus on lifestyle modifications, including regular exercise, a heart-healthy diet, smoking cessation, and effective management of risk factors. Myocardial infarction complications can include heart failure, arrhythmias, and recurrent attacks. Continued advancements in myocardial infarction research and myocardial infarction awareness programs are essential for improving outcomes and reducing the global burden of this life-threatening condition.

Learn more about Myocardial Infarction treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Myocardial Infarction Treatment Market

Myocardial Infarction Market

The Myocardial Infarction market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Myocardial Infarction market trends by analyzing the impact of current Myocardial Infarction therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Myocardial Infarction market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Myocardial Infarction market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The myocardial infarction market is driven by several key factors, including the rising global prevalence of cardiovascular diseases, increasing adoption of sedentary lifestyles, poor dietary habits, and aging populations. Advances in diagnostic technologies, such as high-sensitivity troponin assays and improved imaging tools, are enabling earlier and more accurate detection of myocardial infarction. Furthermore, the growing availability of innovative treatment options, including next-generation antiplatelet drugs, thrombolytics, and minimally invasive surgical procedures, continues to support market growth. Government initiatives promoting heart health awareness and preventive care have also contributed to increased patient screening and timely intervention.

However, the market faces several barriers that can hinder its full potential. High treatment costs and limited access to quality healthcare in low- and middle-income countries pose significant challenges. Delayed diagnosis due to a lack of awareness, especially in rural or underserved regions, can result in poor outcomes. Additionally, stringent regulatory requirements for new drug approvals and the complex nature of clinical trials in cardiology can slow the development of novel therapies. Despite these hurdles, ongoing research, improved healthcare infrastructure, and an emphasis on preventive cardiology are expected to continue driving the myocardial infarction market forward.

According to DelveInsight, the Myocardial Infarction market in 7MM is expected to witness a major change in the study period 2020-2034.

Myocardial Infarction Epidemiology

The Myocardial Infarction epidemiology section provides insights into the historical and current Myocardial Infarction patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Myocardial Infarction market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Myocardial Infarction Epidemiology @ Myocardial Infarction Prevalence

Myocardial Infarction Drugs Uptake

This section focuses on the uptake rate of the potential Myocardial Infarction drugs recently launched in the Myocardial Infarction market or expected to be launched in 2020-2034. The analysis covers the Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Myocardial Infarction Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Myocardial Infarction market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Myocardial Infarction Pipeline Development Activities

The Myocardial Infarction report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Myocardial Infarction key players involved in developing targeted therapeutics.

• INSPRA (eplerenone): Pfizer
• PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
• BRILINTA (ticagrelor): AstraZeneca
• PRALUENT (alirocumab): Regeneron/Sanofi
• FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
• JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
• Olpasiran: Amgen
• And Many Others.

Request for a sample report to understand more about the Myocardial Infarction pipeline development activities @ Myocardial Infarction Medication and Companies

Myocardial Infarction Therapeutics Assessment

Major key companies are working proactively in the Myocardial Infarction Therapeutics market to develop novel therapies which will drive the Myocardial Infarction treatment markets in the upcoming years are Novartis (SWX: NOVN), AstraZeneca (LSE: AZN), Recardio, Idorsia Pharmaceuticals (SWX: IDIA), Eli Lilly and Company (NYSE: LLY), Boehringer Ingelheim, Pfizer (NYSE: PFE), Bayer (ETR: BAYN), Mesoblast, Inc. (ASX: MSB), The Medicines Company (Acquired by Novartis), Mitsubishi Tanabe Pharma (TSE: 4508), Athera Biotechnologies, Hoffmann-La Roche (SWX: ROG), and others.

Learn more about the emerging Myocardial Infarction therapies & key companies @ Myocardial Infarction Clinical Trials and AFDA Approvals

Myocardial Infarction Report Key Insights

1. Myocardial Infarction Patient Population

2. Myocardial Infarction Market Size and Trends

3. Key Cross Competition in the Myocardial Infarction Market

4. Myocardial Infarction Market Dynamics (Key Drivers and Barriers)

5. Myocardial Infarction Market Opportunities

6. Myocardial Infarction Therapeutic Approaches

7. Myocardial Infarction Pipeline Analysis

8. Myocardial Infarction Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Myocardial Infarction Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Myocardial Infarction Competitive Intelligence Analysis

4. Myocardial Infarction Market Overview at a Glance

5. Myocardial Infarction Disease Background and Overview

6. Myocardial Infarction Patient Journey

7. Myocardial Infarction Epidemiology and Patient Population

8. Myocardial Infarction Treatment Algorithm, Current Treatment, and Medical Practices

9. Myocardial Infarction Unmet Needs

10. Key Endpoints of Myocardial Infarction Treatment

11. Myocardial Infarction Marketed Products

12. Myocardial Infarction Emerging Therapies

13. Myocardial Infarction Seven Major Market Analysis

14. Attribute Analysis

15. Myocardial Infarction Market Outlook (7 major markets)

16. Myocardial Infarction Access and Reimbursement Overview

17. KOL Views on the Myocardial Infarction Market

18. Myocardial Infarction Market Drivers

19. Myocardial Infarction Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myocardial Infarction Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

“Critical Limb Ischemia Market”

(Albany, USA) DelveInsight’s “Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Critical Limb Ischemia, historical and forecasted epidemiology as well as the Critical Limb Ischemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Critical Limb Ischemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Critical Limb Ischemia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Critical Limb Ischemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Critical Limb Ischemia market.

Request for a Free Sample Report @ Critical Limb Ischemia Market Forecast

Some facts of the Critical Limb Ischemia Market Report are:

• According to DelveInsight, the Critical Limb Ischemia market size in USA was USD 1,367 million in 2023.
• Leading Critical Limb Ischemia companies working in the market are Boston Scientific Corporation, AnGes, Inc., Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, Medtronic Endovascular, Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Inc, Hemostemix Inc., Caladrius Biosciences, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, BioGenCell Ltd., Abbott Medical Devices and others.
• Key Critical Limb Ischemia Therapies expected to launch in the market are REX-001, Temsirolimus Adventitial Delivery, Collategene, ACP-01, Honedra (CLBS12), RJX (Rejuveinix), YQ23, BGC101, Esprit BTK Device, and others.
• In October 2024, Surmodics, Inc. (Nasdaq: SRDX), a prominent medical device and in vitro diagnostics company, announced that it had received FDA 510(k) clearance for its PounceTM XL Thrombectomy System.
• In April 2024, Abbott re-entered the bioabsorbable stent space with FDA approval for its Esprit BTK System-a drug-eluting scaffold designed to reopen below-the-knee arteries in patients with chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease.
• In March 2024, Elixir Medical received FDA Breakthrough Device Designation for its DynamX® BTK System, an adaptive implant designed to treat below-the-knee (BTK) vessel blockages in patients with chronic limb-threatening ischemia (CLTI).
• In March 2024, BIOTRONIK received FDA Breakthrough Device Designation for its FreesolveTM below-the-knee resorbable magnesium scaffold (BTK RMS), designed for chronic limb-threatening ischemia (CLTI) patients. CLTI, the most severe form of peripheral artery disease (PAD), affects 11% of the 200 million PAD sufferers worldwide and is linked to high amputation rates, mortality, and healthcare costs.In February 2024, Cell Biopeutics Resources Sdn Bhd announced results of an Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.

Critical Limb Ischemia Overview

Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD) characterized by chronic ischemic rest pain, non-healing wounds, or gangrene in the limbs. Critical Limb Ischemia symptoms include persistent pain in the feet or toes, ulcers, and tissue loss, often leading to severe mobility issues or amputation if left untreated. Critical Limb Ischemia causes typically stem from advanced atherosclerosis, where narrowed arteries restrict blood flow to the extremities.

Critical Limb Ischemia diagnosis involves physical examination, ankle-brachial index (ABI), imaging techniques like duplex ultrasound, CT angiography, or MR angiography to assess blood flow and vascular blockages. Early Critical Limb Ischemia detection is essential for preventing complications and improving limb salvage rates.

Critical Limb Ischemia treatment focuses on restoring adequate blood flow through medical management, endovascular procedures, or surgical revascularization. In advanced cases, Critical Limb Ischemia management may also require wound care, pain control, and risk factor modification such as smoking cessation and diabetes management.

Critical Limb Ischemia prognosis is poor without timely intervention, emphasizing the need for awareness and early care. Ongoing Critical Limb Ischemia research is exploring novel therapies to improve outcomes and reduce the risk of major amputations, enhancing quality of life for affected patients.

Learn more about Critical Limb Ischemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Critical Limb Ischemia Treatment Market

Critical Limb Ischemia Market

Critical Limb Ischemia (CLI) represents a significant challenge in healthcare due to its potential for severe complications such as amputation and mortality. The market dynamics surrounding CLI have been evolving as a result of various factors. One key driver is the increasing prevalence of diabetes and vascular diseases, which are major risk factors for CLI. The aging population in many parts of the world also contributes to the rising incidence of CLI, creating a larger patient pool in need of treatment.

Additionally, advancements in medical technology have spurred market growth, with the development of innovative therapies such as drug-eluting stents, bioresorbable stents, and minimally invasive procedures. These technologies offer more effective and less invasive treatment options for CLI patients, driving demand in the market. Moreover, there has been a growing focus on early diagnosis and intervention, leading to increased awareness among healthcare professionals and patients alike. This shift towards proactive CLI management is expected to further fuel market expansion as it reduces the overall healthcare burden associated with advanced stages of the disease, improving patient outcomes and quality of life.

Download the report to understand which factors are driving Critical Limb Ischemia market trends @ Critical Limb Ischemia Market Outlook

Critical Limb Ischemia Treatment Market

Management of CLI often involves a multifaceted approach, with the primary goal of restoring blood flow to the affected limb. This typically begins with lifestyle modifications such as smoking cessation and maintaining a healthy diet. Medications, such as antiplatelet agents and anticoagulants, are commonly prescribed to reduce blood clotting and improve circulation. Additionally, minimally invasive procedures like angioplasty and stenting can be utilized to open blocked arteries and enhance blood flow. In more advanced cases, surgical options such as bypass grafting may be necessary to reroute blood around the blockage, thereby salvaging the limb.

Close monitoring and follow-up care are integral aspects of CLI treatment, as the condition requires ongoing management to prevent recurrence and monitor for potential complications. Patients often undergo rehabilitation programs to improve mobility and reduce the risk of further vascular issues. In severe instances where limb preservation is not feasible, amputation may be considered as a last resort. Through a combination of medical therapies, interventions, and lifestyle adjustments, clinicians strive to improve quality of life, enhance limb function, and mitigate the serious consequences associated with Critical Limb Ischemia.

Critical Limb Ischemia Epidemiology

The Critical Limb Ischemia epidemiology section provides insights into the historical and current Critical Limb Ischemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Critical Limb Ischemia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Critical Limb Ischemia Epidemiology @ Critical Limb Ischemia Prevalence

Critical Limb Ischemia Drugs Uptake

This section focuses on the uptake rate of the potential Critical Limb Ischemia drugs recently launched in the Critical Limb Ischemia market or expected to be launched in 2020-2034. The analysis covers the Critical Limb Ischemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Critical Limb Ischemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Critical Limb Ischemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Critical Limb Ischemia Pipeline Development Activities

The Critical Limb Ischemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Critical Limb Ischemia key players involved in developing targeted therapeutics.

Critical Limb Ischemia Therapeutics Assessment

Major key companies are working proactively in the Critical Limb Ischemia Therapeutics market to develop novel therapies which will drive the Critical Limb Ischemia treatment markets in the upcoming years are Boston Scientific Corporation (NYSE: BSX), AnGes, Inc. (TYO: 4563), Mitsubishi Tanabe Pharma (TYO: 4508), B. Braun Melsungen AG, Medtronic Endovascular (NYSE: MDT), Ixaka Ltd (formerly Rexgenero), Mercator MedSystems, Hemostemix Inc. (TSXV: HEM), Caladrius Biosciences (NASDAQ: CLBS), Reven Pharmaceuticals, New Beta Innovation Limited, BioGenCell Ltd. (Private), Abbott Medical Devices (NYSE: ABT) and others.

Learn more about the emerging Critical Limb Ischemia therapies & key companies @ Critical Limb Ischemia Clinical Trials and FDA Approvals

Critical Limb Ischemia Report Key Insights

1. Critical Limb Ischemia Patient Population

2. Critical Limb Ischemia Market Size and Trends

3. Key Cross Competition in the Critical Limb Ischemia Market

4. Critical Limb Ischemia Market Dynamics (Key Drivers and Barriers)

5. Critical Limb Ischemia Market Opportunities

6. Critical Limb Ischemia Therapeutic Approaches

7. Critical Limb Ischemia Pipeline Analysis

8. Critical Limb Ischemia Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Critical Limb Ischemia Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Critical Limb Ischemia Competitive Intelligence Analysis

4. Critical Limb Ischemia Market Overview at a Glance

5. Critical Limb Ischemia Disease Background and Overview

6. Critical Limb Ischemia Patient Journey

7. Critical Limb Ischemia Epidemiology and Patient Population

8. Critical Limb Ischemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Critical Limb Ischemia Unmet Needs

10. Key Endpoints of Critical Limb Ischemia Treatment

11. Critical Limb Ischemia Marketed Products

12. Critical Limb Ischemia Emerging Therapies

13. Critical Limb Ischemia Seven Major Market Analysis

14. Attribute Analysis

15. Critical Limb Ischemia Market Outlook (7 major markets)

16. Critical Limb Ischemia Access and Reimbursement Overview

17. KOL Views on the Critical Limb Ischemia Market

18. Critical Limb Ischemia Market Drivers

19. Critical Limb Ischemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Critical Limb Ischemia Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Pipeline, Epidemiology and Companies by DelveInsight